Loading...
NPI 1124316138 · Duarte, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Path Md Inc is a clinical medical laboratory provider located in Duarte, California. This profile covers 46 Medicare and 37 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Path Md Inc |
| Address | 931 Buena Vista St Ste 200a |
| City | Duarte |
| State | CA |
| ZIP | 91010 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 12, 2011 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $8.2M |
| Medicare | $6.1M |
PATH MD INC is a clinical medical laboratory with strong volume in SARS–CoV–2 and other respiratory pathogen testing, as evidenced by Medicare top codes 87637, U0003, and U0005 and Medicaid top codes U0003 and 87637; these molecular and multiplex testing CPT/HCPCS indicate the operation is heavily focused on high-throughput infectious disease diagnostics rather than primarily surgical pathology services. The provider’s Medicare revenue totals $6.1M while Medicaid revenue totals $8.2M, so Medicaid is the larger single-source payer in lifetime revenue terms, but both payers represent material streams to the business. Revenue concentration is high for both payers: the top three Medicare codes account for 68.5% of Medicare revenue and the top three Medicaid codes account for 82.2% of Medicaid revenue, indicating the business relies on a small set of test types for the majority of billed revenue. On Medicare the provider is a national outlier for several key codes: 87637 ranks #7 of 1141 providers nationally and is described as an "extreme outlier," and G0416 and 88344 also rank in the 99th percentile; those rankings indicate PATH MD operates at volumes far above typical national peers for certain high-revenue tests. On Medicaid the provider has very large volume in U0003 specifically (91.5K claims, $5.3M revenue) and ranks #28 of 751 in-state (96th percentile), which positions PATH MD as an above-typical, high-volume state provider for high-throughput COVID PCR testing. Several ancillary pathology and immunostain codes (88305, 88344, 88342, 88312, 88313) appear across both payers but contribute only modest shares individually, suggesting the lab maintains some surgical pathology and immunohistochemistry capability in addition to its dominant infectious disease testing line. PATH MD’s NPI was enumerated on 2011-07-12 (~15 years ago), indicating the entity has an established operational history that predates the COVID era and likely supported rapid scale-up of molecular testing during the pandemic. The pattern of code-level percentiles and the presence of multiple codes labeled "extreme outlier" or "notably above typical national volume" signals that PATH MD is a major volume provider for specific high-throughput infectious-agent tests at national (Medicare) and state (Medicaid) levels, while its overall code mix shows concentration risk if demand for those few high-volume tests declines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
46 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 21,570 | $140 | $3M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 10,500 | $70 | $777.1K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 6,210 | $60 | $341.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 10,490 | $30 | $262.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11,210 | $20 | $257.7K |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 750 | $290 | $216.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6,160 | $30 | $209.6K |
| 88344 | The lab analyst applies a single multiplex antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 1,210 | $150 | $181.2K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 5,230 | $30 | $130.8K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 1,430 | $80 | $117.5K |
Showing 1–10 of 46
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
46 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 34 | 110 | 1,340 | $30 | $338.2K |
| U0003 | 9 | 130 | 730 | $70 | $246.4K |
| 87507 | 5 | 10 | 50 | $410 | $167K |
| 88120 | 12 | 20 | 120 | $400 | $122.8K |
| G2023 | 6 | 90 | 1,030 | $20 | $110.9K |
| U0005 | 9 | 150 | 780 | $20 | $75.1K |
| 87481 | 23 | 100 | 270 | $30 | $72.7K |
| 87636 | 27 | 90 | 40 | $140 | $70.6K |
| 87637 | 2 | 190 | 20 | $140 | $61.9K |
| 88121 | 2 | 10 | 30 | $310 | $59.8K |
Showing 1–10 of 46
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
37 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 91,540 | $60 | $5.3M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 12,290 | $80 | $934.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 41,200 | $10 | $453.2K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 6,730 | $50 | $343.2K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 1,030 | $240 | $247.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,960 | $50 | $145K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 7,900 | $20 | $126.5K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 2,690 | $30 | $91.4K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 2,360 | $30 | $73.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,640 | $20 | $61.8K |
Showing 1–10 of 37
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
37 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 28 | 750 | 950 | $50 | $890K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 15 | 250 | 800 | $110 | $625.7K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 196 | 280 | 730 | $90 | $315.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 81 | 290 | 220 | $210 | $268.3K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 398 | 1,140 | 530 | $20 | $195.6K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 155 | 830 | 880 | $40 | $195.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 419 | 1,270 | 450 | $20 | $183.5K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 63 | 210 | 280 | $10 | $160.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 121 | 500 | 530 | $20 | $128.1K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 84 | 300 | 250 | $10 | $121.5K |
Showing 1–10 of 37
Other providers in the same ZIP code as Path Md Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| City Of Hope National Medical Center | CA | General Acute Care Hospital | $0 | $175.7M |
| City Of Hope Medical Foundation | CA | Hematology & Oncology Physician | $0 | $40.6M |
| Amrita Krishnan | CA | Hematology (Internal Medicine) Physician | $1.2M | $0 |
| Arya Amini | CA | Radiation Oncology Physician | $412.9K | $0 |
| Phuc Le | CA | Ophthalmology Physician | $322K | $0 |
| Brady Miller | CA | Urology Physician | $318.2K | $0 |
| Thomas Deguzman | CA | Physical Therapist | $305.9K | $0 |
| Sydney Chung | CA | Physician Assistant | $289.7K | $0 |
| Cathie Chung | CA | Medical Oncology Physician | $251.6K | $0 |
| Hyun Kim | CA | Radiation Oncology Physician | $210.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.